ClinicalTrials.gg
RecruitingNCT06222099HEARTFELTUpdated Nov 16, 2026

The HEARTFELT Study

An interventional study of Heartfelt Device installed and Standard care in Heart Failure and Chronic Heart Failure, sponsored by Heartfelt Technologies. Recruiting at 4 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Heartfelt Technologies · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.
Updated Nov 16, 2026Primary completion movedEligibility revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,500
Allocation
Randomized
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,159 studies in Heart Failure with a site in United States — 346 open to participants now, 439 under way, 27 of them phase 3. Heart Failure · United States.

Planned enrollment
108th of 1,602
1,500 · median 66
Started
2025
with 107 others
No phase
887 of 2,159
159 open now
Primary completion
2028-12
later than 343 of 438 live
Registered
1,872nd of 2,159
by date

Among the 2,159 studies in Heart Failure with a site in United States, this one is the 108th largest by planned enrollment of the 1,602 interventional ones that give a count, is one of 108 that started in 2025, is one of 887 with no phase, reaches primary completion later than 343 of the 438 other live ones, and was the 1,872nd registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

346 of the 2,159 studies in Heart Failure with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,159 studies in Heart Failure with a site in United States, or all of them as a file.
02

Study summary

This pragmatic randomized crossover trial looks at the effect(s) of using a remote patient monitoring device (Heartfelt device) with health alerts to monitor the development of peripheral edema in patients with heart failure (HF). The hypothesis is that this passive measurement method will lead to better data availability, which in turn will improve patient care and reduce hospitalizations for the management of worsening HF (HF hospitalizations, HFHs) in nonadherent participants with chronic HF. The study objectives are:

  • Primary objective: Establish if the Heartfelt device is safe to use and effective at reducing HFHs.
  • Secondary objectives:

    1. Establish the effect of the Heartfelt device on data availability compared to existing remote monitoring devices.
    2. Establish the effect of the Heartfelt device on HF clinical outcomes.

Participants will need to:

  • Install the device in their home for at least a year and up to 4 additional years after.
  • Reply to remote patient monitoring phone calls to follow the care plans.
Read the detailed description

Participants will be recruited through Remote Patient Monitoring Providers (RPMPs) based in the US, using crossover randomization between standard care and Heartfelt device usage with health alerts sent to RPMPs. The RPMPs will follow a protocolized intervention when responding to raised alerts.

The study design is a crossover randomization between:

  • Standard care (control), 162 days: The device is installed in the home and captures data but no health alerts are sent, and the RPMP does not receive data from the device. (Health alerts are generated and stored for review at the end of the study period to correlate with health issues which occurred during usual care).
  • Standard care + Heartfelt (intervention), 162 days: The device captures data and transmits volume measurements and health alerts to the RPMP for review. RPMPs follow a pre-specified alert protocol, potentially following up with the patient.

At consent, patients get randomized to an install date over a period from 21 to 60 days following consent, subject to scheduling this at least 14 days after the most recent recorded hospital discharge at the time of consent, or the discharge from their current hospitalization if hospitalized at the time of consent.

Total study length is 366 days (days 0 to 365). There are two 21-day "washout" periods to prevent carryover between study arms. The first washout period extends from day 0-20 inclusive, and the second from day 183-203 inclusive

At the completion of both crossover arms, patients will be offered the opportunity to keep the device for as long as the study remains active (potentially up to an additional 4 years, for those patients recruited early in the study). During this long-term follow-up, the device will be placed in "Intervention" mode, with randomized 100-day periods where the device is switched into "Standard care" mode (control).

03

Conditions studied

  • Heart Failure
  • Chronic Heart Failure

Browse trials for

Keywords

  • remote patient monitoring
  • chronic heart failure
  • heart failure
  • non-adherent heart failure
04

Who can participate

The criteria were revised on the registry on Nov 16, 2026. See what changed

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated form (wet or digital signature)
  2. Male or female, aged 22 to [No maximum age]
  3. Diagnosed with Chronic Heart failure at least 2 months prior to randomization
  4. Documented history of peripheral edema (edema in feet and lower legs), defined as at least one clinical mention in the medical record indicative of oedema during prior clinical assessment.
  5. Evidence of heart failure decompensation or elevated risk of future hospitalization, defined by one or more of the following:

    1. Hospitalization for heart failure occurring at least once in the past 6 months or at least twice in the past 12 months; OR
    2. Receipt of intravenous/subcutaneous diuretic therapy for heart failure (inpatient or outpatient setting) occurring at least once in the past 6 months or at least twice in the past 12 months; OR
    3. Emergency department or urgent care visit for heart failure decompensation, occurring at least once in the past 6 months or at least twice in the past 12 months; OR
    4. Clinician assessment that the participant is at high risk of heart failure hospitalization within the next 6-12 months, based on documented recent clinical course (e.g. worsening congestion, escalating diuretic requirements, recurrent decompensation, and/or comorbidity burden).
  6. Patients who are prescribed diuretics (daily or PRN).
  7. Evidence of non-adherence defined by one or more of the following:

    1. Participants with ≥180 days of historical monitoring/device data available

      • Failure to collect ≥50% of expected days of prescribed home physiological monitoring data (e.g. weight, blood pressure, or other clinician-recommended measurements), assessed over a continuous 180-day period; OR
      • Discontinuation from a remote patient monitoring/home monitoring program due to non-adherence; OR
      • Failure to adhere to a prescribed home-based therapy/monitoring intervention, supported by device usage data showing \<50% of expected days of use over a continuous 180-day period.
    2. Participants without ≥180 days of historical monitoring/device data available: Evidence of non-adherence may be demonstrated by low data capture over shorter windows, defined as any of the following :

      • ≤2 days of monitoring data recorded for each of the most recent 4 consecutive weeks during which any remote monitoring device was continuously available in the patient's home; OR
      • ≤3 days of monitoring data recorded in any consecutive 8 week period period during which any remote monitoring device was continuously available in the patient home; AND/OR
    3. Documented non-adherence in the medical record within the last 3 years:

      • Historical documentation of persistent medication and/or dietary non-adherence, defined as either a clear statement of ongoing non-adherence or ≥2 documented instances of non-adherence concerns (including dosing and/or timing, where available); OR
      • Historical documentation on repeated clinical assessments indicating persistent difficulty adhering to recommended self-management activities (e.g. repeated failure to follow monitoring instructions, incomplete engagement with care plan, or repeated non-attendance at scheduled reviews).
    4. For participants not previously enrolled in RPM or without sufficient historical monitoring data, non-adherence will be assessed prospectively using connected scales provided at study initiation. Objective adherence metrics derived from scale usage during the initial monitoring period will be used both to characterise baseline adherence and to support predefined subgroup analyses.
    5. Clinical teams/PIs discretion as patients being non-adherent.
  8. For females of : use of highly effective for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 6 weeks after the end of the study.
  9. Patients who are covered by an insurance plan that covers IDE-B costs (e.g. Medicare Part-B), OR written contract signed by the patient, or their provider or payor, stating that they will be liable for any trial-associated costs that Medicare would ordinarily cover if the patient were covered by Medicare.

Exclusion criteria

EXCLUSION CRITERIA

  1. Participant has bandages to lower limbs every day
  2. Participant has an amputation of both feet
  3. Participant is a regular wheelchair user inside their home
  4. Participant is bed-bound
  5. Participant is of no fixed abode
  6. Participant is taking part in a conflicting evaluation/study that could confound the results of this evaluation and/or impact clinical interventions and participant outcomes
  7. Participant is unable to take diuretics
  8. Participant is on a regular schedule of dialysis
  9. Participant has a history of recurrent leg or feet deep vein thrombosis (DVT) (two or more episodes within the last 12 months).
  10. Participant has a history of recurrent leg or feet cellulitis episodes (two or more episodes within the last 12 months).
  11. Participant is prescribed diltiazem or verapamil on an ongoing basis.
  12. Participant is pregnant or is not taking medically approved if of .
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
1,500 participants (estimated)

Study arms

  • Active comparator
    Standard Care (control)

    Device is installed and data is captured but volume measurements and health alerts are not transmitted to the RPMP.

    Device: Heartfelt Device installed · Other: Standard care · Other: Questionnaires

  • Experimental
    Standard Care + Heartfelt (intervention)

    Device is installed and data is captured, and volume measurements and health alerts are transmitted to the RPMP for review and potential follow-up (per a pre-specified alert protocol).

    Device: Heartfelt Device installed · Other: Standard care · Device: Heartfelt-guided care · Other: Questionnaires

Interventions

  • DeviceHeartfelt Device installed

    Device installed in the patient's home and capturing foot volume data which are processed in the cloud.

    Also known as: Remote patient monitoring device

  • OtherStandard care

    RPMPs in regular contact with patients and collecting health monitoring data as per their standard operating procedures.

    Also known as: Daily weighing, Breathlessness, Dizziness, Tiredness

  • DeviceHeartfelt-guided care

    Volume measurements and health alerts transmitted to the RPMP for review. RPMPs follow a pre-specified alert protocol, potentially following up with the patient.

    Also known as: Daily weighing, Remote patient monitoring

  • OtherQuestionnaires

    Patients were presented with one or more optional questionnaires (some validated, some bespoke)

    Also known as: KCCQ, 5Q-5D, PAM Questionnaire, Bespoke Questionnaire

06

What researchers measure

Primary outcomes

  1. Heart Failure Events (HFEs, a composite of HFH or Worsening HF event without hospitalization (as defined in [1-Abraham])

    Used to demonstrate whether the device effectively reduces HFHs and urgent HF visits.

    Time frame: 12 months, plus up to 48 months long term follow-up

  2. Doubling in serum creatinine (sCr) from baseline with at least 2.0mg/dL

    Used to ensure that increased diuretic treatment following alerts from the device does not lead to significant increase in AKI

    Time frame: 12 months, plus up to 48 months long term follow-up

Secondary outcomes

  1. Difference in data availability (device generated or contemporaneous self-report)

    Used to measure the data availability from the Heartfelt device. One of the key findings from feasibility trials and pilot studies in the UK have demonstrated an increased data availability. Does this study in the US confirm the previous finding?

    Time frame: 12 months, plus up to 48 months long term follow-up

  2. The date and length (in hours) of hospital admission and re-admissions

    Used to review the lead time of health alerts, or the lack of health alerts generated prior to hospital admissions.

    Time frame: 12 months, plus up to 48 months long term follow-up

  3. Cause of hospitalizations (HF or non-HF)

    Used to review the lead time of health alerts, or the lack of health alerts generated prior to hospital admissions.

    Time frame: 12 months, plus up to 48 months long term follow-up

  4. Date of increase in HF medications when the patient is home or in the community (not the detailed changes whilst on the ward)

    This may include oral diuretic, IV diuretics and subcutaneous furosemide injections. Used to allow the determination if an outpatient appointment is HF related or not.

    Time frame: 12 months, plus up to 48 months long term follow-up

  5. Death and cause of death from the clinical record (HF or non-HF as defined in [1-Abraham])

    Used to establish if using the device changes HF- or non-HF mortality.

    Time frame: 12 months, plus up to 48 months long term follow-up

  6. Loss of independence (patient unable to live at home; for example, relocation to a care facility for an indefinite duration)

    Used to establish if there has been an effect on the ability of the patient to live independently in their home.

    Time frame: 12 months, plus up to 48 months long term follow-up

  7. Route of admission for hospitalization events (ICU, CCU, or ward admission),and discharge (home, skilled nursing facility and long term care facility).

    Used to establish if using the device changes the scheduling and/or setting of care and/or route of admission.

    Time frame: 12 months, plus up to 48 months long term follow-up

  8. Scheduling of care events (scheduled or unscheduled)

    Used to establish if using the device changes the scheduling and/or setting of care and/or route of admission.

    Time frame: 12 months, plus up to 48 months long term follow-up

  9. The setting of care events (inpatient or outpatient)

    Used to establish if using the device changes the scheduling and/or setting of care and/or route of admission.

    Time frame: 12 months, plus up to 48 months long term follow-up

  10. Date and time of health alerts generated by the Heartfelt device

    Used to establish the response time to health alerts.

    Time frame: 12 months, plus up to 48 months long term follow-up

  11. Date, time and method of contact made following reception of a health alert generated by the Heartfelt device

    Used to establish the response time to health alerts.

    Time frame: 12 months, plus up to 48 months long term follow-up

  12. Date and reason for study withdrawal

    Used alongside the analysis of other right-censoring endpoints.

    Time frame: 12 months, plus up to 48 months long term follow-up

Other outcomes

  1. NT Pro-BNP or BNP, with date if available in patient records

    Used to correlate NT Pro-BNP health alert status.

    Time frame: 12 months, plus up to 48 months long term follow-up

  2. Date and time of health alerts from other monitoring devices

    Used to correlate health alerts from other medical devices and the Heartfelt device.

    Time frame: 12 months, plus up to 48 months long term follow-up

  3. Symptoms diary (if available)

    Used to establish patient usage of symptom diaries.

    Time frame: 12 months, plus up to 48 months long term follow-up

  4. Questionnaire responses (if available)

    Used to establish patient acceptability of the device.

    Time frame: 12 months, plus up to 48 months long term follow-up

  5. Dates, types and length of stays in rehab facilities/nursing home/care homes

    Recorded in hours if \<48h and in days if \>48h. Proxy used to identify trends in worsening of patient's health/independence/quality of life following participation in various arms of the study.

    Time frame: 12 months, plus up to 48 months long term follow-up

  6. Dates and times of caregivers' shifts if home healthcare used

    Proxy used to identify trends in worsening of patient's health/independence/quality of life following participation in various arms of the study.

    Time frame: 12 months, plus up to 48 months long term follow-up

  7. HFHs in the 12 months prior to installation (as defined in [1-Abraham])

    Used to compare HF Hospitalization date before the study as a baseline period and during the study.

    Time frame: Retrospectively, over the 12 months prior to device installation

  8. UHFV and other urgent healthcare usage in the 12 months prior to installation

    Used to compare Heart Failure Visit numbers before the study as a baseline period and during the study.

    Time frame: Retrospectively, over the 12 months prior to device installation

  9. Date and cause of Death

    Used to supplement data on HF-related death that is collected as a primary endpoint from clinical records of participants, as well as allowing the comparison to non-participants.

    Time frame: 12 months

  10. Ethnicity

    Used to analyze the other endpoints based on this subgroup.

    Time frame: At enrollment

  11. NYHA class

    Used to analyze the other endpoints based on this subgroup.

    Time frame: At enrollment

  12. Ejection fraction

    Used to analyze the other endpoints based on this subgroup.

    Time frame: At enrollment

  13. Comorbidities

    Used to analyze the other endpoints based on this subgroup.

    Time frame: At enrollment

  14. Date, prescription fulfillment and any modifications to dosage of HF medications (if available)

    Used to get an indication of medication adherence.

    Time frame: 12 months, plus up to 48 months long term follow-up

  15. Optimal medical therapy score (if available)

    Used to get an indication of medication adherence.

    Time frame: 12 months, plus up to 48 months long term follow-up

  16. Presence of edema reported by clinicians during the clinical encounter (including grading of edema if available)

    Used to validate the device's determination of edema status.

    Time frame: 12 months, plus up to 48 months long term follow-up

  17. Data availability (device generated or contemporaneous self-report) in the 6 months prior to screening.

    Used to analyze the other endpoints based on this subgroup.

    Time frame: Retrospectively, over the 6 months prior to screening

  18. Device-related complications

    Used to ensure that any device-related complications that occur after the main 12 months of the study are captured.

    Time frame: 12 months, plus up to 48 months long term follow-up

  19. Date, time, reason and means of contact made with patients by RPMPs not due to Heartfelt health alerts (e.g. phone triage/counseling, repeat labs, etc)

    Used to determine if any significant changes in outcomes might be due to increases in patient contacts overall.

    Time frame: 12 months, plus up to 48 months long term follow-up

  20. Tobacco consumption

    Used to determine if any significant changes in outcomes might be due to lifestyle choices and to analyze the other endpoints based on this subgroup.

    Time frame: 12 months, plus up to 48 months long term follow-up

  21. Alcohol consumption

    Used to determine if any significant changes in outcomes might be due to lifestyle choices and to analyze the other endpoints based on this subgroup.

    Time frame: 12 months, plus up to 48 months long term follow-up

  22. Cannabis consumption

    Used to determine if any significant changes in outcomes might be due to lifestyle choices and to analyze the other endpoints based on this subgroup.

    Time frame: 12 months, plus up to 48 months long term follow-up

  23. Other recreational drug(s) consumption

    Used to determine if any significant changes in outcomes might be due to lifestyle choices and to analyze the other endpoints based on this subgroup.

    Time frame: 12 months, plus up to 48 months long term follow-up

  24. Cause of hospitalizations (ICD-10-CM codes)

    Used to determine if a correlation could be identified between treatment effect and type of hospital stays; as well as sensitivity and specificity of the alert analysis.

    Time frame: 12 months, plus up to 48 months long term follow-up

07

Study locations

2 of 4 sites recruiting
  • Baptist Health
    Little Rock, Arkansas 72205, United States
    Active, not recruiting

    Not enrolling at this site.

  • Suncare Medicare Center/Suncare Research Center
    Miami, Florida 33135, United States
    Not yet recruiting
  • HealthArc
    Hackensack, New Jersey 07601, United States
    Recruiting
    • Kaitlyn Batch-Monteforte, BSN., RN. · Contactkaitlyn@healtharc.io · 201-992-5561
    • Kaitlyn Batch-Monteforte, BSN., RN. · Principal investigator
  • Connect America
    Bala-Cynwyd, Pennsylvania 19004, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Data collected for this study will be analyzed and stored by the Sponsor. After the study is completed, the de-identified, archived data will be transmitted to and stored by the Sponsor, for use by other researchers including those outside of the study. Permission to transmit data to the Sponsor will be included in the informed consent. To further reduce the risk of patient identification, we will not associate patients with a named RPMP, we will instead use a site ID for each RPMP. During the conduct of the study, an individual participant can choose to withdraw consent to have their de-identified data stored for future research. However, withdrawal of consent with regard to data storage may not be possible after the study is completed. When the study is completed, access to study de-identified data will be provided through the Sponsor.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 6 months after publication

Access criteria: Contact the Sponsor

Data sharing details ↗ · www.hftech.org

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Dec 2028, 38 months after the start.

Of 236 industry-sponsored interventional studies with no phase under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 61. This study's planned 38 months is above that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

Primary completion moved twice since we started tracking on Sep 25, 2026: Dec 2026 → Dec 2028, last on Nov 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2024
First posted
Jan 24, 2024
StartActual
Oct 23, 2025
Primary completionEst.
Dec 31, 2028was Dec 2026
CompletionEst.
Dec 31, 2030
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Suncare Medicare Center/Suncare Research Center · Miami, United States
Nov 16, 2026
Primary completion
Dec 31, 2026→Dec 31, 2028
moved 2 times, Oct 14, 2026 – Nov 16, 2026
Eligibility
Criteria revised in 2 updates
What changed on Oct 19, 2026
  • RemovedINCLUSION CRITERIA:
  • Removeda.Hospitalization for heart failure occurring at least once in the past 6 months or at least twice in the past 12 months; OR b.Receipt of intravenous/subcutaneous diuretic therapy for heart failure (inpatient or outpatient setting) occurring at least once in the past 6 months or at least twice in the past 12 months; OR c.Emergency department or urgent care visit for heart failure decompensation, occurring at least once in the past 6 months or at least twice in the past 12 months; OR d.Clinician assessment that the participant is at high risk of heart failure hospitalization within the next 6-12 months, based on documented recent clinical course (e.g. worsening congestion, escalating diuretic requirements, recurrent decompensation, and/or comorbidity burden).
  • Removed1. Participant has bandages to lower limbs every day 2. Participant has an amputation of both feet 3. Participant is a regular wheelchair user inside their home 4. Participant is bed-bound 5. Participant is of no fixed abode 6. Participant is taking part in a conflicting evaluation/study that could confound the results of this evaluation and/or impact clinical interventions and participant outcomes 7. Participant is unable to take diuretics 8. Participant is on a regular schedule of dialysis 9. Participant has a history of recurrent leg or feet deep vein thrombosis (DVT) (two or more episodes within the last 12 months).
Inclusion criteria
  • AddedHospitalization for heart failure occurring at least once in the past 6 months or at least twice in the past 12 months; OR
  • AddedReceipt of intravenous/subcutaneous diuretic therapy for heart failure (inpatient or outpatient setting) occurring at least once in the past 6 months or at least twice in the past 12 months; OR
  • AddedEmergency department or urgent care visit for heart failure decompensation, occurring at least once in the past 6 months or at least twice in the past 12 months; OR
  • AddedClinician assessment that the participant is at high risk of heart failure hospitalization within the next 6-12 months, based on documented recent clinical course (e.g. worsening congestion, escalating diuretic requirements, recurrent decompensation, and/or comorbidity burden).
  • Edited● Failure to collect ≥50% of expected days of prescribed home physiological monitoring data (e.g. weight, blood pressure, or other clinician-recommended measurements), assessed over a continuous 180-day period; OR
  • Edited● Discontinuation from a remote patient monitoring/home monitoring program due to non-adherence; OR
  • Edited● Failure to adhere to a prescribed home-based therapy/monitoring intervention, supported by device usage data showing <50% of expected days of use over a continuous 180-day period.
  • Edited● ≤2 days of monitoring data recorded for each of the most recent 4 consecutive weeks during which any remote monitoring device was continuously available in the patient's home; OR
  • Edited● ≤3 days of monitoring data recorded in any consecutive 8 week period period during which any remote monitoring device was continuously available in the patient home; AND/OR
Exclusion criteria
  • AddedParticipant has bandages to lower limbs every day
  • AddedParticipant has an amputation of both feet
  • AddedParticipant is a regular wheelchair user inside their home
  • AddedParticipant is bed-bound
  • AddedParticipant is of no fixed abode
  • AddedParticipant is taking part in a conflicting evaluation/study that could confound the results of this evaluation and/or impact clinical interventions and participant outcomes
  • AddedParticipant is unable to take diuretics
  • AddedParticipant is on a regular schedule of dialysis
  • AddedParticipant has a history of recurrent leg or feet deep vein thrombosis (DVT) (two or more episodes within the last 12 months).
  • AddedParticipant is prescribed diltiazem or verapamil on an ongoing basis.
  • Edited11. Participant is prescribed diltiazem or verapamil on an ongoing basis. 12. Participant is pregnant or is not taking medically approved birth control if of child-bearing potential.
What changed on Nov 16, 2026
Inclusion criteria
  • EditedPatients who are treated with prescribed diuretics (daily diureticsor PRN).
  • Editedby documentedDocumented non-adherence in the medical record within the last 3 years:
across 2 updates, Oct 19, 2026 – Nov 16, 2026
Show all 3 updates
  1. Nov 16, 2026
    1 site added
    Show site
    • Suncare Medicare Center/Suncare Research Center · Miami, United States
    Primary completion Jan 1, 2028→Dec 31, 2028
    Eligibility 2 inclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedPatients who are treated with prescribed diuretics (daily diureticsor PRN).
    • Editedby documentedDocumented non-adherence in the medical record within the last 3 years:
    + 1 other change: verification date
  2. Oct 19, 2026
    Eligibility 5 inclusion criteria edited, 4 added; 1 exclusion criterion edited, 10 added; 3 criteria removed
    What changed in the criteria
    • RemovedINCLUSION CRITERIA:
    • Removeda.Hospitalization for heart failure occurring at least once in the past 6 months or at least twice in the past 12 months; OR b.Receipt of intravenous/subcutaneous diuretic therapy for heart failure (inpatient or outpatient setting) occurring at least once in the past 6 months or at least twice in the past 12 months; OR c.Emergency department or urgent care visit for heart failure decompensation, occurring at least once in the past 6 months or at least twice in the past 12 months; OR d.Clinician assessment that the participant is at high risk of heart failure hospitalization within the next 6-12 months, based on documented recent clinical course (e.g. worsening congestion, escalating diuretic requirements, recurrent decompensation, and/or comorbidity burden).
    • Removed1. Participant has bandages to lower limbs every day 2. Participant has an amputation of both feet 3. Participant is a regular wheelchair user inside their home 4. Participant is bed-bound 5. Participant is of no fixed abode 6. Participant is taking part in a conflicting evaluation/study that could confound the results of this evaluation and/or impact clinical interventions and participant outcomes 7. Participant is unable to take diuretics 8. Participant is on a regular schedule of dialysis 9. Participant has a history of recurrent leg or feet deep vein thrombosis (DVT) (two or more episodes within the last 12 months).
    Inclusion criteria
    • AddedHospitalization for heart failure occurring at least once in the past 6 months or at least twice in the past 12 months; OR
    • AddedReceipt of intravenous/subcutaneous diuretic therapy for heart failure (inpatient or outpatient setting) occurring at least once in the past 6 months or at least twice in the past 12 months; OR
    • AddedEmergency department or urgent care visit for heart failure decompensation, occurring at least once in the past 6 months or at least twice in the past 12 months; OR
    • AddedClinician assessment that the participant is at high risk of heart failure hospitalization within the next 6-12 months, based on documented recent clinical course (e.g. worsening congestion, escalating diuretic requirements, recurrent decompensation, and/or comorbidity burden).
    • Edited● Failure to collect ≥50% of expected days of prescribed home physiological monitoring data (e.g. weight, blood pressure, or other clinician-recommended measurements), assessed over a continuous 180-day period; OR
    • Edited● Discontinuation from a remote patient monitoring/home monitoring program due to non-adherence; OR
    • Edited● Failure to adhere to a prescribed home-based therapy/monitoring intervention, supported by device usage data showing <50% of expected days of use over a continuous 180-day period.
    • Edited● ≤2 days of monitoring data recorded for each of the most recent 4 consecutive weeks during which any remote monitoring device was continuously available in the patient's home; OR
    • Edited● ≤3 days of monitoring data recorded in any consecutive 8 week period period during which any remote monitoring device was continuously available in the patient home; AND/OR
    Exclusion criteria
    • AddedParticipant has bandages to lower limbs every day
    • AddedParticipant has an amputation of both feet
    • AddedParticipant is a regular wheelchair user inside their home
    • AddedParticipant is bed-bound
    • AddedParticipant is of no fixed abode
    • AddedParticipant is taking part in a conflicting evaluation/study that could confound the results of this evaluation and/or impact clinical interventions and participant outcomes
    • AddedParticipant is unable to take diuretics
    • AddedParticipant is on a regular schedule of dialysis
    • AddedParticipant has a history of recurrent leg or feet deep vein thrombosis (DVT) (two or more episodes within the last 12 months).
    • AddedParticipant is prescribed diltiazem or verapamil on an ongoing basis.
    • Edited11. Participant is prescribed diltiazem or verapamil on an ongoing basis. 12. Participant is pregnant or is not taking medically approved birth control if of child-bearing potential.
  3. Oct 14, 2026
    Primary completion Dec 31, 2026→Jan 1, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06222099
Lead sponsor
Heartfelt Technologies
Responsible party
Sponsor
First posted
Jan 24, 2024
Start date
Oct 23, 2025
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Nov 16, 2026

Study contacts

WH Wilson Tang, MD
Contact
usa.trial@hftech.org
+441223 967250
Amparito Cunningham, MD. MPH.
Contact
amparito@hftech.org
6176425062
WH Wilson Tang, MD
study chair · Cleveland Clinic, USA

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion